Is the price reduction of Acotalon's Quankeli (Bosentan Tablets) because the patent period has expired?

It is an indisputable fact that the patent period of all profits has passed, but there is no imitation that has passed the quality consistency evaluation in China.

If enterprises only pay attention to their own interests, they can keep high prices, but high prices will not benefit more patients with pulmonary hypertension. Therefore, Actaeon decided to change the pricing strategy, directly face patients at low prices, and let more patients achieve full-dose treatment, instead of giving up treatment or reducing treatment for economic reasons to delay their illness.